JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishimori, T.
Right arrow Articles by Wahl, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishimori, T.
Right arrow Articles by Wahl, R. L.
Journal of Nuclear Medicine Vol. 46 No. 5 752-757
© 2005 by Society of Nuclear Medicine


Clinical Investigations

Detection of Unexpected Additional Primary Malignancies with PET/CT

Takayoshi Ishimori, MD, PhD1, Pavni V. Patel, MD1 and Richard L. Wahl, MD1

1 Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland

This study evaluated the yield of whole-body 18F-FDG PET/CT for the detection of unexpected 18F-FDG-avid additional primary malignant tumors in patients being evaluated by PET/CT for known or suspected malignances. Methods: Reports from whole-body 18F-FDG PET/CT scans from June 2001 to June 2003 were reviewed, and 1,912 patients (924 men and 988 women; mean age ± SD, 58.9 ± 13.9 y) who had been scanned for known or suspected malignant lesions were included in this study. The sites of known or suspected primary tumors included lung (28.6%), colon or rectum (12.4%), head or neck (12.1%), lymph nodes (10.9%), breast (7.6%), gynecologic organs (7.1%), genitourinary organs (4.2%), esophagus (3.6%), skin (melanoma) (3.5%), pancreas (2.5%), bone or soft tissue (2.2%), and other sites (5.4%). Lesions that were newly discovered on PET/CT, had not been previously detected by other modalities, and were atypical in location for metastases on the PET/CT study were interpreted as suggestive of a new primary malignant tumor. These abnormalities were compared with the final diagnosis obtained from the medical records, including pathologic reports. Results: PET-positive lesions suggestive of new primary malignant tumors were found in 79 (4.1%) of 1,912 patients. In 22 (1.2%) of 1,912 patients, these lesions were pathologically proven to be malignant. Proven sites were lung (7 lesions), thyroid (6 lesions), colon (4 lesions), breast (2 lesions), esophagus (2 lesions), bile duct (1 lesion), and head and neck other than thyroid (1 lesion). Two new lesions in the lung and the thyroid were proven malignant in 1 patient. In 17 patients, the treatment plan was changed and the new lesion was surgically resected after the PET/CT examination. In 10 patients, PET was falsely positive after pathologic assessment. False-positive sites included thyroid (5 lesions), uterus (2 lesions), head and neck other than thyroid (2 lesions), and lung (1 lesion). In 8 patients, the PET-positive lesions were considered benign after clinical follow-up of at least 8 mo. In 39 patients, the follow-up record was not yet available and the final diagnosis of the detected lesion has not yet been resolved. Conclusion: Whole-body PET/CT detected new, unexpected 18F-FDG-avid primary malignant tumors in at least 1.2% of patients with cancer.

Key Words: additional primary malignancy • PET/CT • 18F-FDG


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  



This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
C. Are, J. F. Hsu, R. A. Ghossein, H. Schoder, J. P. Shah, and A. R. Shaha
Histological Aggressiveness of Fluorodeoxyglucose Positron-Emission Tomogram (FDG-PET)-Detected Incidental Thyroid Carcinomas
Ann. Surg. Oncol., November 1, 2007; 14(11): 3210 - 3215.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon
FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations
RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. F. Glockner
Incidental Findings on Renal MR Angiography
Am. J. Roentgenol., September 1, 2007; 189(3): 693 - 700.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
W. De Wever, Y. Vankan, S. Stroobants, and J. Verschakelen
Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer
Eur. Respir. J., May 1, 2007; 29(5): 995 - 1002.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
C. Are, J. F. Hsu, H. Schoder, J. P. Shah, S. M. Larson, and A. R. Shaha
FDG-PET Detected Thyroid Incidentalomas: Need for Further Investigation?
Ann. Surg. Oncol., January 1, 2007; 14(1): 239 - 247.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
J. Nucl. Med., June 1, 2006; 47(6): 957 - 967.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
J. Y. Choi, K. S. Lee, H.-J. Kim, Y. M. Shim, O. J. Kwon, K. Park, C.-H. Baek, J. H. Chung, K.-H. Lee, and B.-T. Kim
Focal Thyroid Lesions Incidentally Identified by Integrated 18F-FDG PET/CT: Clinical Significance and Improved Characterization
J. Nucl. Med., April 1, 2006; 47(4): 609 - 615.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.